Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.
Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine influenza. Unlike the existing inactivated vaccines, Equilis Prequenza Te is the only one able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of two vaccine applications 4-6 weeks apart until the recommended time of the third vaccination. In this paper we describe the duration of immunity profile, tested in an experimental setting according to European legislation, of this inactivated equine influenza and tetanus combination vaccine. In addition to influenza antigen, the formulation contains a second generation ISCOM (the so called ISCOMatrix) as an adjuvant. The vaccine aims at the induction of protection from the primary vaccination course until the time of annual revaccination 12 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) at the time of annual revaccination was evidenced by a significant reduction of clinical signs of influenza, a significant reduction of virus excretion and a significant reduction of fever. The effect of the annual revaccination on the duration of immunity against influenza and tetanus was also studied by serology. For tetanus, as a consequence of the 24 months duration of immunity, an alternating annual vaccination schedule consisting of Prequenza and Prequenza Te is proposed after the first three doses of Prequenza Te.
Heldens
J G M
JG
Intervet Schering Plough Animal Health, Department for Virological R&D, W. de Körverstraat 35, 5831 AN Boxmeer, The Netherlands. jacco.heldens@sp.nobilon.com
Pouwels
H G W
HG
Derks
C G G
CG
Van de Zande
S M A
SM
Hoeijmakers
M J H
MJ
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control*; D006736:Horses / Q000276:immunology; D016882:ISCOMs / Q000276:immunology; D053123:Influenza A Virus, H3N8 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D013742:Tetanus / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D013745:Tetanus Toxoid / Q000276:immunology*; D014611:Vaccination / Q000662:veterinary; D017778:Vaccines, Combined / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D016882:ISCOMs; D007252:Influenza Vaccines; D013745:Tetanus Toxoid; D017778:Vaccines, Combined